Upgrade to SI Premium - Free Trial

Teva bids $57.5M for BioXcel agitation drug in bankruptcy sale

August 28, 2026 6:17 AM
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has placed a stalking horse bid to acquire certain assets from BioXcel ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Mergers and Acquisitions